Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal

Jun 04 2013

• By Lisa LaMotta

Related Content

AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks

Dec 20 2011

Fostamatinib Skates Through OSKIRA-1 With Mixed Results

Apr 05 2013

With Much Riding On Fostamatinib, Rigel Awaits The Phase III Results

Mar 04 2013

Targacept, AstraZeneca Face Another Failure With NNR Class

Mar 20 2012

AZ’s Make Or Break Moment Comes Down To Business Development

Apr 17 2013

AZ Continues To Buy Pipeline With $100M Rigel Deal

Feb 16 2010

Related Companies

Rigel Pharmaceuticals, Inc.

AstraZeneca PLC

AbbVie Inc.

Gyre Therapeutics, Inc.

Additional Topics

Strategy Clinical Trials Deals BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window